Levels of anti-Müllerian hormone (AMH) may not correlate with ovarian reserve in patients with breast cancer, suggests a study presented at ESHRE 2018, thus raising questions on the utility of AMH testing before hormonal stimulation in fertility preservation for women with breast cancer.
Chemotherapy may be less damaging to fertility of female lymphoma patients who are of a younger age than those who are older, even in the case of an alkylating regimen, suggests a study presented at ESHRE 2018.
The increased risk of prostate cancer, particularly early-onset prostate cancer, among subfertile men who undergo intracytoplasmic sperm injection (ICSI) does not appear to be due to the procedure, according to a nationwide, registry-based study from Sweden.
Tubal flushing with oil-based contrast medium at hysterosalpingography (HSG) leads to a higher ongoing pregnancy rate beyond the previously reported results at 6 months, with significantly shorter time to ongoing pregnancy than flushing with water-based contrast, according to a study presented at ESHRE 2018.
Dual triggering with a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) may increase the number of oocytes among women undergoing in vitro fertilization (IVF), according to a study presented at ESHRE 2018.
Endometrial scratching prior to in vitro fertilization (IVF) failed to improve live birth rates in the PIP* study, challenging a practice currently embraced by gynaecologists to boost the chances of embryo implantation in subfertile women.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.